10X Genomics: The Hidden Turnaround Stock in a Market That Could Be Bigger Than AI

What if there's an industry that could be bigger than AI — and the leading company in it trades 85% below its highs, is profitable, and almost nobody's talking about it?

That's 10X Genomics (ticker: TXG), and this is the stock on my radar that excites me most right now.

What Spatial Biology Actually Changes

When a doctor suspects disease today, they take a biopsy and examine tissue under a microscope. They can tell whether cells look normal or abnormal. What they cannot tell you is what those cells are doing. Which ones are aggressive. Which are dormant. Which will spread.

It's like looking at a city from an airplane and trying to figure out which buildings have people in them. You can see the structures, but you can't see the life inside.

Spatial biology changes this fundamentally. It lets scientists see inside individual cells at the molecular level — not just identifying what cells are present, but understanding what they're doing. How they communicate with each other. Which ones are dangerous.

Imagine mapping every cell in a tumor and knowing exactly which ones to target with treatment, years before a conventional test would catch the problem. That's the capability 10X Genomics is building. And they're the market leader.

The Turnaround in Numbers

Market cap: approximately $3.7 billion. Stock price: 85% below all-time highs.

Look past the chart carnage, and the numbers tell a recovery story.

The company has aggressively cut expenses. Margins have improved meaningfully. Last quarter, they beat earnings estimates by a wide margin. Revenue came in at $150 million, above expectations. Full-year guidance was raised to $600 million or more.

Costs going down. Revenue going up. Margins expanding. This is the textbook pattern of a turnaround gaining traction.

Cash reserves remain substantial with a controlled burn rate. R&D investment continues, protecting competitive positioning. The high margins indicate strong willingness-to-pay from customers — this isn't a commodity product being sold at thin margins.

Two Catalysts on the Horizon

First: the Xaira platform, launching in the second half of this year. Xaira is designed to take spatial biology from research laboratories into clinical settings. This isn't incremental improvement — it's a market expansion play that could meaningfully grow 10X's addressable market. Lives will be saved by this technology.

Second: the partnership with AI company Bio Optimus to launch Stella, a spatial data initiative that combines 10X's spatial biology capabilities with artificial intelligence. Humans examining molecular-level data inevitably make errors. AI doesn't. The combination of spatial biology and AI could fundamentally change diagnostic accuracy.

What the Chart Reveals

Zoomed out, the stock chart shows an 85% decline from peak. A cautionary tale for unconditional buy-and-hold investors.

Zoomed in on recent months, a different picture emerges. A heartbeat pattern — consistent lows and highs within a defined range — has formed, and the stock is beginning to break out upward from this consolidation.

For turnaround stocks, this pattern deserves attention. It can mark the early stages of a new trend after a prolonged decline. The theoretical upside from current levels to prior highs is measured in hundreds of percent. Expecting full recovery is unrealistic, but meaningful re-rating is plausible if the fundamental improvement continues alongside new product launches.

The Risk You Have to Accept

Turnaround stories carry a specific risk: sometimes they turn around one more time — back down.

Management could revert to excessive spending. The Xaira platform could underperform expectations. The spatial biology market's growth could prove slower than projected. These are real possibilities.

But at current valuations, consider what the market is pricing: a company leading in spatial biology, with improving financials, strategic AI partnerships, and a clinical expansion platform launching imminently — all at 85% below previous highs.

This isn't the safest stock on any list. It's not the most predictable. What makes it compelling is the asymmetry: if the turnaround continues, the upside could be extraordinary. And almost no one is paying attention. In my experience, that's precisely where the most interesting opportunities hide.

FAQ

Q: What makes spatial biology potentially bigger than AI? A: AI optimizes existing processes. Spatial biology creates entirely new diagnostic and therapeutic capabilities that didn't exist before — the ability to understand disease at the individual cell level. Every cancer diagnosis, every drug development program, every precision medicine treatment could be transformed. The total addressable market spans the entire healthcare system, not just the tech sector.

Q: Why is the stock down 85% if the technology is so promising? A: Growth companies routinely experience massive drawdowns when they fail to meet inflated expectations. 10X went through a period of overspending and underwhelming growth that shattered investor confidence. What's changed is that management has cut costs aggressively, margins are improving, revenue is growing again, and new products are launching. The market hasn't yet priced in this improvement.

Q: How does the Bio Optimus partnership with Stella work? A: Stella combines 10X's spatial biology data — detailed molecular-level cell mapping — with AI analysis. Humans examining molecular data at this scale inevitably make errors and miss patterns. AI can process vastly more data with greater consistency. The partnership aims to make spatial biology analysis faster, more accurate, and more accessible to clinical settings beyond specialized research labs.